Treatment with a proteasome inhibitor, bortezomib, for thalidomide-resistant multiple myeloma
A proteasome inhibitor with a new molecular target (PS-341: bortezomib) was recently developed, and its efficacy in the treatment of refractory multiple myeloma has been reported in the United States. Here, we present a 54-year-old Japanese male patient with refractory multiple myeloma resistant to...
Saved in:
Published in | Rinshō ketsueki Vol. 45; no. 2; p. 144 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | Japanese |
Published |
Japan
01.02.2004
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Abstract | A proteasome inhibitor with a new molecular target (PS-341: bortezomib) was recently developed, and its efficacy in the treatment of refractory multiple myeloma has been reported in the United States. Here, we present a 54-year-old Japanese male patient with refractory multiple myeloma resistant to thalidomide. In 1998, the patient was diagnosed as having multiple myeloma (IgG-kappa) and underwent chemotherapy, autologous hematopoietic cell transplantation and interferon therapy, but the disease recurred. In December 2002, thalidomide and high-dose dexamethasone therapy was initiated, and while this combination therapy was effective at first, the multiple myeloma became unresponsive. On 23 June 2003, bortezomib therapy with the following regime was therefore started: 2.2 mg (1.3 mg/m2) of bortezomib was injected intravenously on days 1, 4, 8 and 11, and after a one-week break, another cycle was performed. Starting on day 8 of the administration, the serum total protein, IgG, serum calcium and LDH levels decreased rapidly, and after day 45 of the administration, blood transfusion was no longer needed. Since this is the first report of the use of bortezomib in the treatment of refractory multiple myeloma in Japan, further monitoring of this patient will provide extremely valuable information for developing a therapy against this disease. |
---|---|
AbstractList | A proteasome inhibitor with a new molecular target (PS-341: bortezomib) was recently developed, and its efficacy in the treatment of refractory multiple myeloma has been reported in the United States. Here, we present a 54-year-old Japanese male patient with refractory multiple myeloma resistant to thalidomide. In 1998, the patient was diagnosed as having multiple myeloma (IgG-kappa) and underwent chemotherapy, autologous hematopoietic cell transplantation and interferon therapy, but the disease recurred. In December 2002, thalidomide and high-dose dexamethasone therapy was initiated, and while this combination therapy was effective at first, the multiple myeloma became unresponsive. On 23 June 2003, bortezomib therapy with the following regime was therefore started: 2.2 mg (1.3 mg/m2) of bortezomib was injected intravenously on days 1, 4, 8 and 11, and after a one-week break, another cycle was performed. Starting on day 8 of the administration, the serum total protein, IgG, serum calcium and LDH levels decreased rapidly, and after day 45 of the administration, blood transfusion was no longer needed. Since this is the first report of the use of bortezomib in the treatment of refractory multiple myeloma in Japan, further monitoring of this patient will provide extremely valuable information for developing a therapy against this disease. |
Author | Noborio-Hatano, Kaoru Takahashi, Satoko Ozawa, Keiya Komatsu, Norio Mori, Masaki Muroi, Kazuo Kikuchi, Satoru Takatoku, Masaaki |
Author_xml | – sequence: 1 givenname: Masaaki surname: Takatoku fullname: Takatoku, Masaaki – sequence: 2 givenname: Kaoru surname: Noborio-Hatano fullname: Noborio-Hatano, Kaoru – sequence: 3 givenname: Satoko surname: Takahashi fullname: Takahashi, Satoko – sequence: 4 givenname: Satoru surname: Kikuchi fullname: Kikuchi, Satoru – sequence: 5 givenname: Masaki surname: Mori fullname: Mori, Masaki – sequence: 6 givenname: Kazuo surname: Muroi fullname: Muroi, Kazuo – sequence: 7 givenname: Norio surname: Komatsu fullname: Komatsu, Norio – sequence: 8 givenname: Keiya surname: Ozawa fullname: Ozawa, Keiya |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/15045823$$D View this record in MEDLINE/PubMed |
BookMark | eNo1j01LwzAYgHOYuDl39yT5Aet889WmRxl-wcDLPMpI2zcs2jQlSZH56x2op4fn8sBzRWZDGJCQGwYbxiSUd9ENn5jTtJFqw6SckQVIrQomRT0nq5RcA8A158DFJZkzBVJpLhbkfR_RZI9Dpl8uH6mhYwwZTQoeqRuOrnE5xDVtQsz4Hbxr1tSGSPPR9K47e4dFxORSNueEn_rsxh6pP2EfvLkmF9b0CVd_XJK3x4f99rnYvT69bO93xQfTIhec66ptSsErbaysSyVZC7VWthVSqYp3ALLsSqgsCAF1W-pWGgFK6ZpbYSxfktvf7jg1HrvDGJ038XT4_-Q_zVFXqQ |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM |
DOI | 10.11406/rinketsu.45.144 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
ExternalDocumentID | 15045823 |
Genre | English Abstract Journal Article Case Reports |
GroupedDBID | ACGFS ALMA_UNASSIGNED_HOLDINGS CGR CUY CVF ECM EIF JSP NPM RJT |
ID | FETCH-LOGICAL-j183t-2287cb63278af496541c0985fc345572d0046d607f03309c68c4a3055892f3af2 |
ISSN | 0485-1439 |
IngestDate | Thu May 23 23:08:30 EDT 2024 |
IsPeerReviewed | false |
IsScholarly | true |
Issue | 2 |
Language | Japanese |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-j183t-2287cb63278af496541c0985fc345572d0046d607f03309c68c4a3055892f3af2 |
PMID | 15045823 |
ParticipantIDs | pubmed_primary_15045823 |
PublicationCentury | 2000 |
PublicationDate | 2004-Feb |
PublicationDateYYYYMMDD | 2004-02-01 |
PublicationDate_xml | – month: 02 year: 2004 text: 2004-Feb |
PublicationDecade | 2000 |
PublicationPlace | Japan |
PublicationPlace_xml | – name: Japan |
PublicationTitle | Rinshō ketsueki |
PublicationTitleAlternate | Rinsho Ketsueki |
PublicationYear | 2004 |
SSID | ssib002822023 ssj0059168 ssib008799715 ssib009993986 ssib023167872 ssib000393816 ssib005879785 ssib006571151 ssib000940419 ssib020751763 |
Score | 1.6634636 |
Snippet | A proteasome inhibitor with a new molecular target (PS-341: bortezomib) was recently developed, and its efficacy in the treatment of refractory multiple... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | 144 |
SubjectTerms | Antineoplastic Agents - administration & dosage Antineoplastic Agents - therapeutic use Boronic Acids - administration & dosage Boronic Acids - therapeutic use Bortezomib Drug Resistance, Neoplasm Humans Male Middle Aged Multiple Myeloma - drug therapy Protease Inhibitors - administration & dosage Protease Inhibitors - therapeutic use Pyrazines - administration & dosage Pyrazines - therapeutic use Thalidomide - therapeutic use |
Title | Treatment with a proteasome inhibitor, bortezomib, for thalidomide-resistant multiple myeloma |
URI | https://www.ncbi.nlm.nih.gov/pubmed/15045823 |
Volume | 45 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV07b9swECacdulSpOg7bcGhmRK6Ch8iORZGC6ODpwTIUgSkJMKKazOI5aH5Ff3JPYp6EG6KPhbBEE0K4n04fUcev0PoPaNGcS0ZoVZnJJS6J1YoR7LMOK60zblrsy0W-fyCf7kUl5PJjyRradfYaXF377mS_7Eq3AO7hlOy_2DZYVC4Ab_BvnAFC8P172w8ZInHI2onreqC2fp1kAJZ1rZuYjRuQ0rtnV_X7e5LzCwEAl7CnbIiEHEHFgnDDOmF6-_VN9-57F6-u95sl_54NjtW_GRVNWCvVT0G_uEg0moXj_9sjRmbFj5U3_JkbuARPmZw-Ntd2nMZKjrF9WkYxI95AatQqqVv6Pr0SxS8z2oePBlXggAx06nbjSqSHbxo4kPPoiDkr74duAdY5BZi9PCOUy6me38F69ysW1sDzQ0bguzPrXtq233TATqQKnjMRbr6w3TYZ03oKc9SObyQkpsldEsoqVMtoVxIIOCjP4VmLRM6BmSd6VHOjwKdO5OjPBoNqgVKDvJoAqh9yzT66e234WGiPuxNU1t-Kr7aXgDVEqnzQ_S4i4DwxwjnJ2hybZ6irwOUcYAyNniEMh6gfIpHIJ9igDG-F8a4hzHuYPwMXXz-dD6bk67yB7mGT0xDKMTxhc0ZlQpchg616otMK-EKxoWQtAzLOmWeSZcxlukiVwU3QbtOaeqYcfQ5erDxm-olwsJZYavKwJet4NpKW6jcAAMwJfSgTr1CL-JsXN1EeZerfp5e_7blCD0aYf4GPXTgT6q3QE4b-65FzE9mXYGB |
link.rule.ids | 786 |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Treatment+with+a+proteasome+inhibitor%2C+bortezomib%2C+for+thalidomide-resistant+multiple+myeloma&rft.jtitle=Rinsho%CC%84+ketsueki&rft.au=Takatoku%2C+Masaaki&rft.au=Noborio-Hatano%2C+Kaoru&rft.au=Takahashi%2C+Satoko&rft.au=Kikuchi%2C+Satoru&rft.date=2004-02-01&rft.issn=0485-1439&rft.volume=45&rft.issue=2&rft.spage=144&rft_id=info:doi/10.11406%2Frinketsu.45.144&rft_id=info%3Apmid%2F15045823&rft_id=info%3Apmid%2F15045823&rft.externalDocID=15045823 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0485-1439&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0485-1439&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0485-1439&client=summon |